Mangalam Drugs & Organics

Mangalam Drugs & Organics

49.35

+2.35

(5.00%)

Market Cap

78.11 Cr

PE Ratio

-2.41

Volume

1,01,606.00

Day High - Low

49.35 - 49.35

52W High-Low

116.02 - 22.80

compare with

Sun Pharmaceutical

1,675.40 (+0.39%)

Divis Laboratories

6,140.00 (-1.54%)

Torrent Pharmaceuticals

4,086.60 (+1.70%)

Cipla

1,392.30 (-0.37%)

Lupin

2,177.10 (-0.04%)

Key Fundamentals

Market Cap

78.11 Cr

EPS

4.25

PE Ratio

-2.41

PB Ratio

0.62

Book Value

76.13

EBITDA

36.30

Dividend Yield

0.00 %

Industry

Sector

Pharmaceuticals

Return on Equity

4.51

Debt to Equity

0.73

Actual

Company News

Mangalam Drugs Reports Q3 FY26 Loss, Key Resignations

4 days ago

Mangalam Drugs & Organics posted consolidated net loss of ₹983.55 lakhs in Q3 FY26 vs profit of ₹128.68 lakhs in Q3 FY25. CFO and Company Secretary resigned citing health and career reasons.

Mangalam Drugs Clarifies No Material Info on Price Move

Jan 07, 2026

Mangalam Drugs & Organics responds to BSE surveillance query, stating no material information pending disclosure and attributing price movements to market sentiment.

Mangalam Drugs CFO Ajay Samant Resigns

Dec 24, 2025

Mangalam Drugs & Organics announces CFO Ajay Samant's resignation effective March 31, 2025, due to attainment of retirement age as per company guidelines.

View more

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,675.40	#1 4,01,984.58	38.20	#1 54,729.00	9.71	#1 10,980	2.89	34.79
Divis Laboratories	6,140.00	1,62,997.71	66.59	9,712.00	18.67	2,191	35.10	33.94
Torrent Pharmaceuticals	4,086.60	1,38,309.11	63.56	11,539.40	6.99	1,911	30.46	69.74
Cipla	1,392.30	1,12,466.07	20.78	28,409.50	7.12	5,291	3.71	25.16
Lupin	2,177.10	99,449.67	22.87	22,909.50	13.74	3,306	#1 72.75	60.00
Dr Reddys Laboratories	1,167.20	97,418.06	#1 17.10	33,741.20	16.73	5,725	-0.38	23.29
Zydus Life Science	881.10	88,659.28	17.36	23,511.00	18.55	4,615	34.60	36.61
Mankind Pharma	2,117.20	87,399.09	50.64	12,744.20	#1 20.90	2,007	-21.05	40.03
Alkem Laboratories	5,748.00	68,725.96	28.95	13,458.30	3.70	2,216	10.98	54.82
Aurobindo Pharma	1,167.60	67,814.40	19.90	32,345.60	9.43	3,484	3.81	41.61

Growth Rate

Revenue Growth

-13.56 %

Net Income Growth

-173.63 %

Cash Flow Change

989.26 %

ROE

-167.51 %

ROCE

571.43 %

EBITDA Margin (Avg.)

140.00 %

Quarterly Financial Results

Quarterly Financials	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025
Revenue	97	102	77	80	89	73	57	49	59
Expenses	90	91	68	71	80	63	62	52	60
EBITDA	7	12	8	9	9	10	-5	-3	-1
Operating Profit %	7 %	11 %	11 %	11 %	10 %	14 %	-8 %	-6 %	-3 %
Depreciation	4	4	4	4	4	5	5	5	5
Interest	3	4	4	4	4	4	4	5	4
Profit Before Tax	0	4	1	1	1	2	-13	-13	-10
Tax	-1	0	-2	-2	0	2	1	-5	0
Net Profit	1	4	3	3	1	0	-14	-7	-10
EPS in ₹	0.31	2.23	1.70	1.70	0.81	0.04	-8.72	-4.64	-6.21

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2024	2025
Total Assets	334	366
Fixed Assets	148	163
Current Assets	176	199
Capital Work in Progress	8	3
Investments	0	0
Other Assets	178	201
Total Liabilities	334	366
Current Liabilities	164	192
Non Current Liabilities	34	26
Total Equity	136	149
Reserve & Surplus	120	133
Share Capital	16	16

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2024	2025
Net Cash Flow	-3	1
Investing Activities	-12	-20
Operating Activities	4	43
Financing Activities	5	-22

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025
Promoter	50.53 %	50.53 %	50.53 %	50.53 %	50.53 %	50.42 %	50.42 %	50.32 %	50.32 %	50.32 %	50.32 %	50.32 %	50.32 %	50.32 %	50.30 %	50.30 %	50.30 %	50.30 %	50.30 %
FIIs	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.10 %	0.26 %	0.21 %	0.11 %	0.11 %	0.47 %	0.53 %	0.11 %
DIIs	0.01 %	0.01 %	0.01 %	0.01 %	0.01 %	0.01 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Government	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	44.27 %	42.68 %	44.53 %	44.39 %	43.85 %	44.18 %	44.12 %	44.27 %	44.22 %	44.64 %	44.54 %	44.43 %	44.22 %	44.70 %	44.91 %	44.78 %	44.55 %	44.53 %	45.00 %
Others	5.19 %	6.78 %	4.93 %	5.07 %	5.61 %	5.40 %	5.46 %	5.41 %	5.46 %	5.05 %	5.14 %	5.15 %	5.20 %	4.77 %	4.67 %	4.80 %	4.68 %	4.63 %	4.59 %
No of Share Holders	0	20,520	21,827	21,071	20,668	20,084	18,988	18,483	17,943	17,890	17,978	18,610	19,173	19,312	19,508	19,679	19,697	19,728	19,881

Corporate Action

Record Date	Corporate Action	Information	Announcement Day	LTP at Annoucement	LTP at Record Day
26 Sept 2024	Annual General Meeting	NA	26 Sept 2024	130.33	124.37
14 Nov 2024	Quarterly Result Announcement	NA	14 Nov 2024	110.36	105.03
13 Feb 2025	Quarterly Result Announcement	NA	13 Feb 2025	109.00	110.75
17 May 2025	Quarterly Result Announcement	NA	17 May 2025	78.66	82.30
07 Aug 2025	Quarterly Result Announcement	NA	07 Aug 2025	87.56	84.03
12 Aug 2025	Extraordinary General Meeting	NA	12 Aug 2025	85.56	77.13
29 Sept 2025	Annual General Meeting	NA	29 Sept 2025	78.43	72.22
20 Nov 2025	Quarterly Result Announcement	NA	20 Nov 2025	66.04	54.61
15 Jan 2026	Quarterly Result Announcement	NA	15 Jan 2026	33.42	44.77

Announcements

Announcement under Regulation 30 (LODR)-Change in Management

Announcement under Regulation 30 (LODR)-Resignation of Director

Announcement under Regulation 30 (LODR)-Newspaper Publication

Announcement under Regulation 30 (LODR)-Change in Management

Declaration Of Un-Audited Financial Results For The Quarter Ended 31St December 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 15Th January 2026 Inter Alia To Approve Un-Audited Financial Results For The Quarter Ended 31St December 2025

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

Board Meeting Intimation for Declaration Of Un-Audited Financial Results For The Quarter Ended 31St December 2025.

Revert To The Query Raised By BSE Surveillance Department Dated 5Th January 2026 Regarding Clarification In Price Movement.

Clarification sought from Mangalam Drugs & Organics Ltd

Closure of Trading Window

Explanation To The Intimation Filed On 29Th March 2025 Regarding Resignation Of Chief Financial Officer Of The Company.

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Announcement under Regulation 30 (LODR)-Newspaper Publication

Declaration Of Un-Audited Financial Results For The Quarter Ended 30Th September 2025

Board Meeting Outcome for Intimation Of Outcome Of Board Meeting Held On 20Th November 2025 At 12:00 P.M. To Approve Standalone And Consolidated Un-Audited Financial Results For The Quarter Ended 30Th September 2025

Defaults under Para A sub-paragraph 6 of Schedule III-Initial Disclosure

Results-Delay in Financial Results

Board Meeting Intimation for Postponement Of Board Meeting To Be Held On 20Th November 2025

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.

Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 13Th November 2025 To Consider And Approve Un-Audited Financial Results(Standalone And Consolidated) For The Quarter Ended 30Th September 2025.

Announcement under Regulation 30 (LODR)-Newspaper Publication

Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

Shareholder Meeting / Postal Ballot-Scrutinizers Report

Announcement under Regulation 30 (LODR)-Change in Management

Closure of Trading Window

Shareholder Meeting / Postal Ballot-Outcome of AGM

Announcement under Regulation 30 (LODR)-Newspaper Publication

Announcement Under Regulation 30 Of SEBI(LODR)Regulations 2015 For Submission Of Corrigendum For 52Nd Annual Report Of 2024-25.

Reg. 34 (1) Annual Report.

Announcement under Regulation 30 (LODR)-Newspaper Publication

Intimation Of 52Nd Annual General Meeting Of The Company To Be Held On 29Th September 2025 At 3:00 P.M. Through Video Conferencing/ Other Audio Visual Means.

Reg. 34 (1) Annual Report.

Appointment Of Ragini Chokshi & Co. As Secretarial Auditor Of The Company For The Period Of 5 Years Commencing From 1St April 2025 Till 31St March 2030 Subject To Approval Of Shareholders.

Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th Sepetember 2025 For Appointment Of Secretarial Auditor Appointment For A Period Of Five Years Subject To Approval Of Shareholders In The Upcoming Annual General Meeting.

Board Meeting Intimation for Board Meeting Intimation To Be Held On 5Th September 2025 Inter Alia To Approve Appointment Of Secretarial Auditor For The Period Of 5 Years And Re-Appointment Of Director Who Is Retiring By Rotation.

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Intimation Of Voting Results And Scrutinizers Report Of Tribunal Convened Equity Shareholders Meeting Held On 12Th August 2025 At 12.30 P.M.

Intimation Of The Voting Results And Scrutinizers Report For The Tribunal Convened Unsecured Creditors Meeting Held On 12Th August 2025 At 11:00 A.M.

Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.

Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting

Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting

Announcement under Regulation 30 (LODR)-Newspaper Publication

Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025

Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 7Th August 2025 For The Unaudited Financial Results For The Quarter Ending June 2025

Board Meeting Intimation for Notice Of Board Meeting For Approval Of Unaudited Financial Results For 1St Quarter Ending Of 2025-26 To Be Held On 7Th August 2025 At 4:00 P.M.

Technical Indicators

RSI(14)

Overbought

82.19

ATR(14)

Less Volatile

1.74

STOCH(9,6)

Overbought

100.00

STOCH RSI(14)

Overbought

100.00

MACD(12,26)

Bullish

2.66

ADX(14)

Very Strong Trend

51.29

UO(9)

Bearish

97.32

ROC(12)

Uptrend And Accelerating

79.39

WillR(14)

Overbought

0.00